中文
 

Follow us 

Hot Topic
Market News
Events & Promo
Career Tips
Education News
Health & Life
Delonix Bioworks and A*STAR Infectious Diseases Labs Announce Research Collaboration to Advance Novel Engineered OMV Vaccine Candidates Against Klebsiella pneumoniae
PRNewswire

Delonix Bioworks and A*STAR Infectious Diseases Labs Announce Research Collaboration to Advance Novel Engineered OMV Vaccine Candidates Against Klebsiella pneumoniae

Publish date: 16 Nov 2026

Follow us

Stay updated on the job market

Popular Articles

【首富發聲】本港出生率陷全球最低!去年新生兒急跌15.4%,馬斯克預言:若不改變將很快消失
【首富發聲】本港出生率陷全球最低!去年新生兒急跌15.4%,馬斯克預言:若不改變將很快消失
【打工仔減肥必睇】返工越耐越肥?盤點6個辦公室致肥壞習慣!踢走「過勞肥」全攻略
【打工仔減肥必睇】返工越耐越肥?盤點6個辦公室致肥壞習慣!踢走「過勞肥」全攻略
【35歲後的頂級財富】港人公認人生贏家10大清單:你做到幾多個?
【35歲後的頂級財富】港人公認人生贏家10大清單:你做到幾多個?
【QS亞洲大學排名】港5大學強勢列入10強!港大蟬聯亞洲榜首,城大超中大首登全港第二
【QS亞洲大學排名】港5大學強勢列入10強!港大蟬聯亞洲榜首,城大超中大首登全港第二
【天氣轉涼】天文台:今晚急跌明早最低16度!新界溫差極大,打工仔出門必備「洋蔥式著法」
【天氣轉涼】天文台:今晚急跌明早最低16度!新界溫差極大,打工仔出門必備「洋蔥式著法」

SHANGHAI and SINGAPORE, Nov. 16, 2026 /PRNewswire/ -- Delonix Bioworks, a clinical-stage biotechnology company pioneering next-generation outer membrane vesicle (OMV) vaccines, today announced that it has entered into a Research Collaboration Agreement with A*STAR Infectious Diseases Labs (A*STAR IDL), a research institute under Singapore's Agency for Science, Technology and Research (A*STAR).

The collaboration aims to discover and develop novel OMV-based vaccine candidates targeting Klebsiella pneumoniae (K. pneumoniae). By combining Delonix's proprietary pathogenic bacterial genome editing and OMV Plus™ platforms with A*STAR IDL's strong capabilities in translational infectious disease research, clinical relevant bacterial isolates, and immunological evaluation, the collaboration also strengthens Singapore's capabilities to translate infectious disease research towards potential interventions against antimicrobial-resistant pathogens.

K. pneumoniae is a leading cause of life-threatening pneumonia, bloodstream infections, and sepsis, posing severe risks to vulnerable patient populations. The World Health Organization (WHO) has classified carbapenem-resistant Enterobacterales, including K. pneumoniae, as critical-priority pathogens due to high levels of multi-drug resistance against standard clinical therapies [1,2,3].

Despite the significant public health burden, there are currently no licensed vaccines available for K. pneumoniae. Traditional vaccine approaches have been hindered by the pathogen's extensive genetic diversity, thick capsular polysaccharides that mask conserved surface antigens, and high antigenic variation across hypervirulent and multidrug-resistant clinical lineages. Delonix's engineered OMV approach offers a differentiated solution to overcome these barriers. By precisely editing the bacterial genome to modulate capsular interference, detoxify endotoxins, and enrich conserved native antigens on non-replicating vesicles, engineered OMVs has the potential to elicit potent innate and adaptive immune responses capable of broad cross-strain protection.

This partnership marks an important milestone in Delonix's global strategy to build collaborative networks that accelerate the translation of next-generation bacterial vaccines. Driven by a shared commitment to combating antimicrobial resistance (AMR), Delonix and A*STAR IDL will leverage their complementary strengths to generate and evaluate vaccine candidates for safety, immunogenicity, and broad cross-strain protective potential, with the aim of advancing potential preventive approaches against drug-resistant K. pneumoniae.

About Delonix Bioworks

Delonix Bioworks is a clinical-stage biotechnology company at the forefront of developing next-generation genetically engineered bacterial vaccines. Leveraging its proprietary OMV Plus™ platform, the company produces high-yield, cost-effective, and precisely engineered outer membrane vesicles (OMVs) designed for superior antigen presentation and immunogenicity. Delonix is dedicated to advancing a robust pipeline of innovative bacterial vaccine candidates addressing critical unmet needs, including vaccines targeting meningococcal group B (MenB), pertussis, gonorrhoea, and K. pneumoniae infections. Its lead candidate, DX-104, is currently in Phase I clinical trials in Australia and China.

For more information, please visit https://delonixbio.com/.

Business Development & Strategic Partnerships

Email: bd@delonixbio.com

References

[1] WHO. WHO Bacterial Priority Pathogens List, 2024.

[2] WHO. Global Antibiotic Resistance Surveillance Report 2025.

[3] WHO. WHO Warns of Widespread Resistance to Common Antibiotics Worldwide. 2025.

 

Follow us

Stay updated on the job market

Popular Articles

【首富發聲】本港出生率陷全球最低!去年新生兒急跌15.4%,馬斯克預言:若不改變將很快消失
【首富發聲】本港出生率陷全球最低!去年新生兒急跌15.4%,馬斯克預言:若不改變將很快消失
【打工仔減肥必睇】返工越耐越肥?盤點6個辦公室致肥壞習慣!踢走「過勞肥」全攻略
【打工仔減肥必睇】返工越耐越肥?盤點6個辦公室致肥壞習慣!踢走「過勞肥」全攻略
【35歲後的頂級財富】港人公認人生贏家10大清單:你做到幾多個?
【35歲後的頂級財富】港人公認人生贏家10大清單:你做到幾多個?
【QS亞洲大學排名】港5大學強勢列入10強!港大蟬聯亞洲榜首,城大超中大首登全港第二
【QS亞洲大學排名】港5大學強勢列入10強!港大蟬聯亞洲榜首,城大超中大首登全港第二
【天氣轉涼】天文台:今晚急跌明早最低16度!新界溫差極大,打工仔出門必備「洋蔥式著法」
【天氣轉涼】天文台:今晚急跌明早最低16度!新界溫差極大,打工仔出門必備「洋蔥式著法」

Hottest Tags

#馬斯克
#Elon Musk
#香港出生率
#少子化危機
#出生人口下跌
#生育津貼
#人口老化
#育兒成本
#打工仔減肥
#過勞肥
#辦公室致肥習慣
#寫字樓減肥

Contact Us
Notice
Back to Top
We use cookies to enhance your experience on our website. Please read and confirm your agreement to our Privacy Policy and Terms and Conditions before continue to browse our website. Read and Agreed